- Home
- IINN vs GOVX Comparison
IINN vs GOVX Comparison
Compare IINN & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IINN
- GOVX
- Stock Information
- Founded
- IINN 2018
- GOVX 2001
- Country
- IINN Israel
- GOVX United States
- Employees
- IINN N/A
- GOVX N/A
- Industry
- IINN Medical/Dental Instruments
- GOVX Biotechnology: Pharmaceutical Preparations
- Sector
- IINN Health Care
- GOVX Health Care
- Exchange
- IINN Nasdaq
- GOVX Nasdaq
- Market Cap
- IINN 13.7M
- GOVX 15.5M
- IPO Year
- IINN 2021
- GOVX N/A
- Fundamental
- Price
- IINN $0.85
- GOVX $0.95
- Analyst Decision
- IINN Strong Buy
- GOVX Strong Buy
- Analyst Count
- IINN 1
- GOVX 5
- Target Price
- IINN $2.00
- GOVX $12.40
- AVG Volume (30 Days)
- IINN 422.8K
- GOVX 1.5M
- Earning Date
- IINN 08-14-2025
- GOVX 08-05-2025
- Dividend Yield
- IINN N/A
- GOVX N/A
- EPS Growth
- IINN N/A
- GOVX N/A
- EPS
- IINN N/A
- GOVX N/A
- Revenue
- IINN N/A
- GOVX $5,591,576.00
- Revenue This Year
- IINN N/A
- GOVX N/A
- Revenue Next Year
- IINN N/A
- GOVX N/A
- P/E Ratio
- IINN N/A
- GOVX N/A
- Revenue Growth
- IINN N/A
- GOVX N/A
- 52 Week Low
- IINN $0.40
- GOVX $0.73
- 52 Week High
- IINN $1.60
- GOVX $11.18
- Technical
- Relative Strength Index (RSI)
- IINN 63.38
- GOVX 46.22
- Support Level
- IINN $0.70
- GOVX $0.85
- Resistance Level
- IINN $0.77
- GOVX $1.39
- Average True Range (ATR)
- IINN 0.06
- GOVX 0.15
- MACD
- IINN 0.01
- GOVX -0.02
- Stochastic Oscillator
- IINN 75.80
- GOVX 18.52
About IINN Inspira Technologies Oxy B.H.N. Ltd.
Inspira Technologies Oxy BHN Ltd is a specialty medical device company engaged in the research, development, manufacture, and marketing of proprietary respiratory support technology that is intended to provide an alternative to invasive mechanical ventilation (MV), which is the standard of care today for the treatment of respiratory failure. The respiratory care devices market is segmented geographically into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.